Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 1112 results for criteria

  1. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  2. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

  3. OrganOx metra for liver transplant (MIB275)

    NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .

  4. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

  5. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  6. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

  7. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

  8. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  9. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence (CG76)

    This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.

  10. PneuX to prevent ventilator-associated pneumonia (MTG48)

    Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.

  11. Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies.

  12. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.

  13. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

  14. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having extern...

  15. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making